OS Therapies (OSTX) Free Cash Flow (2023 - 2026)
OS Therapies' (OSTX) quarterly Free Cash Flow came in at -$4.6 million in Q1 2026, down 28.07% YoY from -$6.4 million in Q1 2025, and down 24.6% on a QoQ basis from -$3.7 million in Q4 2025.
OS Therapies (OSTX) Free Cash Flow (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Free Cash Flow data on file, last reported at -$4.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 28.07% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.7 million (down 53.18% YoY) and the FY2025 annual result came in at -$14.7 million, down 101.4% from the prior year.
- Free Cash Flow retreated to -$4.6 million in Q1 2026, from -$3.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$428186.0 in Q1 2023 to a low of -$4.7 million in Q3 2025.
- A 4-year average of -$2.3 million and a median of -$2.4 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow fell 6.03% — and 2025, when it sank 459.72%.
- Tracing OSTX's Free Cash Flow over 4 years: stood at -$871160.0 in 2023, then sank by 172.58% to -$2.4 million in 2024, then tumbled by 55.47% to -$3.7 million in 2025, then retreated by 24.6% to -$4.6 million in 2026.
- The last three Free Cash Flow figures came in at -$4.6 million (Q1 2026), -$3.7 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | -5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.60 Mn |
| Mar 31, 2026 | -4.60 Mn |
| Dec 31, 2025 | -3.69 Mn |
| Dec 31, 2025 | -3.69 Mn |
| Sep 30, 2025 | -4.71 Mn |
| Sep 30, 2025 | -4.71 Mn |
| Jun 30, 2025 | -2.68 Mn |
| Jun 30, 2025 | -2.68 Mn |
| Mar 31, 2025 | -3.59 Mn |
| Mar 31, 2025 | -3.59 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Sep 30, 2024 | -3.38 Mn |
| Sep 30, 2024 | -3.38 Mn |
| Jun 30, 2024 | -881,191.00 |
| Jun 30, 2024 | -881,191.00 |
| Mar 31, 2024 | -641,729.00 |
| Mar 31, 2024 | -641,729.00 |
| Dec 31, 2023 | -871,160.00 |
| Dec 31, 2023 | -871,160.00 |